A carregar...
Enzalutamide and blocking androgen receptor in advanced prostate cancer: lessons learnt from the history of drug development of antiandrogens
Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is more effective than its predecessor bicalutamide, which was analyzed in head-to-head studies of patients with CRPC. This family...
Na minha lista:
| Publicado no: | Res Rep Urol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5818862/ https://ncbi.nlm.nih.gov/pubmed/29497605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/RRU.S157116 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|